4RD.F MAAT PHARMA S.A. EO-1

Healthcare Biotechnology Frankfurt Exchange
1.04 EUR
Close of Nov 11, 2026
0.8730 8.20
Market cap
EUR 19.6M
P/E
-
P/B
10.98x
ROE
-1,726.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4RD.F undervalued?

Graham number

The Graham number of MAAT PHARMA S.A. EO-1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MAAT PHARMA S.A. EO-1 fundamental analysis

No fundamental analysis for MAAT PHARMA S.A. EO-1 yet.

MAAT PHARMA S.A. EO-1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MAAT PHARMA S.A. EO-1

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic…

Full company profile